We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-29.74%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
-$369M
(-60%)
Cap. Flow
-$216M
Cap. Flow
% of AUM
-88.84%
Top 10 Holdings %
Top 10 Hldgs %
9.9%
Holding
504
New
52
Increased
49
Reduced
307
Closed
94
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oxford Square Capital
OXSQ
|
+$1.88M |
| 2 |
Newmont
NEM
|
+$1.81M |
| 3 |
Brookfield Renewable
BEP
|
+$1.69M |
| 4 |
XRN
Chiron Real Estate Inc
XRN
|
+$1.68M |
| 5 |
Public Storage
PSA
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Reliance Steel & Aluminium
RS
|
+$4.3M |
| 2 |
Vale
VALE
|
+$4.14M |
| 3 |
DEA
Easterly Government Properties
DEA
|
+$4.07M |
| 4 |
NP
Neenah, Inc. Common Stock
NP
|
+$4.04M |
| 5 |
Arbor Realty Trust
ABR
|
+$3.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.56% |
| 2 | Healthcare | 19.87% |
| 3 | Real Estate | 12.49% |
| 4 | Energy | 9.44% |
| 5 | Materials | 6.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Atara Biotherapeutics
ATRA
$73.6M
| $198K | 0.08% |
931
-136
| -13% | -$43.2K |
|
277
MacroGenics
MGNX
$240M
| $198K | 0.08% |
33,943
-4,962
| -13% | -$45.1K |
|
278
XBiotech
XBIT
$68.3M
| $192K | 0.08% |
18,095
-2,640
| -13% | -$43K |
|
|
ATNX
279
DELISTED
Athenex, Inc. Common Stock
ATNX
| $191K | 0.08% |
1,235
-181
| -13% | -$45.6K |
|
|
BLUE
280
DELISTED
bluebird bio
BLUE
| $184K | 0.08% |
309
-46
| -13% | -$44.8K |
|
|
MYOV
281
DELISTED
Myovant Sciences Ltd.
MYOV
| $180K | 0.07% |
23,895
-3,474
| -13% | -$39K |
|
282
Alaunos Therapeutics
TCRT
$4.59M
| $179K | 0.07% |
486
-71
| -13% | -$36.7K |
|
|
AUTL
283
Autolus Therapeutics
AUTL
$407M
| $170K | 0.07% |
28,428
-4,149
| -13% | -$38.4K |
|
|
SRNE
284
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $163K | 0.07% |
88,342
-12,874
| -13% | -$37.1K |
|
|
GTHX
285
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $160K | 0.07% |
14,563
-2,121
| -13% | -$39.6K |
|
|
PTLA
286
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $159K | 0.07% |
22,368
-1,887
| -8% | -$23.5K |
|
287
Arrowhead Research
ARWR
$12.3B
| $155K | 0.06% |
5,401
-795
| -13% | -$32.1K |
|
288
Gossamer Bio
GOSS
$87.2M
| $144K | 0.06% |
14,166
-2,079
| -13% | -$27.1K |
|
|
CBIO
289
Crescent Biopharma
CBIO
$555M
| $138K | 0.06% |
603
-88
| -13% | -$33.6K |
|
|
ALLK
290
DELISTED
Allakos
ALLK
| $130K | 0.05% |
2,928
-422
| -13% | -$28.9K |
|
291
Amazon
AMZN
$2.53T
| $125K | 0.05% |
1,280
+160
| +14% | +$15.5K |
|
292
Brookfield Infrastructure
BIPC
$5.24B
| $123K | 0.05% |
+5,658
| New | +$123K |
|
293
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.9B
| $100K | 0.04% |
+1,293
| New | +$109K |
|
294
Meta Platforms (Facebook)
META
$1.37T
| $100K | 0.04% |
602
+198
| +49% | +$38.8K |
|
295
Wave Life Sciences
WVE
$1.11B
| $90K | 0.04% |
9,558
-1,390
| -13% | -$11.8K |
|
296
Visa
V
$673B
| $80K | 0.03% |
496
+203
| +69% | +$38.2K |
|
297
UnitedHealth
UNH
$383B
| $66K | 0.03% |
263
+42
| +19% | +$11.6K |
|
298
Adobe
ADBE
$98.5B
| $58K | 0.02% |
181
+34
| +23% | +$11.6K |
|
299
Thermo Fisher Scientific
TMO
$214B
| $54K | 0.02% |
190
+55
| +41% | +$17.3K |
|
300
Mastercard
MA
$510B
| $53K | 0.02% |
220
+35
| +19% | +$10.4K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
RC
TSS
Virtus ETF Advisers's Q1 2020 Portfolio in Review
As of Q1 2020, Virtus ETF Advisers held 504 positions worth $243M, down 60% from $612M the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
Virtus ETF Advisers withdrew a net $216M in Q1 2020, closing 94 positions and reducing 307 holdings. Its most notable exit was Reliance Steel & Aluminium, an estimated $4.3M position sold in full.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Real Estate.
Against the trend, Virtus ETF Advisers opened a new position in Newmont worth $1.82M.
- Virtus ETF Advisers's largest Q1 2020 buy was Newmont: 40,138 shares worth $1.82M.
- Virtus ETF Advisers added most to Oxford Square Capital in Q1 2020, an estimated $1.88M increase.
- Virtus ETF Advisers's biggest Q1 2020 reduction was Air Products & Chemicals, cutting an estimated $3.72M.
- Virtus ETF Advisers fully exited Reliance Steel & Aluminium in Q1 2020, selling an estimated $4.3M.
- Virtus ETF Advisers's ten largest holdings make up 9.9% of its $243M portfolio in Q1 2020.
- Virtus ETF Advisers opened 52 new positions and closed 94 in Q1 2020.
- Virtus ETF Advisers's portfolio value fell 60% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q1 2020, filed 14 May 2020.